Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: A systematic review and meta-analysis

Supportive Care in Cancer

Volumn 20, Issue 11, 2012, Pages 2985-2998

  Lopez Olivo, Maria A ^a   Shah, Nimit A ^a   Pratt, Greg ^a   Risser, Jan M ^b   Symanski, Elaine ^b   Suarez Almazor, Maria E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Bisphosphonates; Bone metastases; Lungcancer neoplasm; Meta analysis; Randomized controlled trials

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; ZOLEDRONIC ACID;

ANALGESIA; BONE DISEASE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; HUMAN; LUNG CANCER; META ANALYSIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PAIN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84868468259     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1563-z     Document Type: Review

References (64)

1. Decroisette C, Monnet I, Berard H, Quere G, Le Caer H, Bota S, Audigier-Valette C, Geriniere L, Vernejoux JM, Chouaid C (2011) Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601). J Thorac Oncol: Official Publication of the International Association for the Study of Lung Cancer 6:576-582
2. O'Donnell P (2012) Metastatic cancer of bone. Orthobullets Available from: http://www.orthobullets.com/pathology/8045/metastaticcancer- of-bone. Accessed on: May 29, 2012
3. De Marinis F, Eberhardt W, Harper PG, Sureda BM, Nackaerts K, Soerensen JB, Syrigos K, Tredaniel J (2009) Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol: Official Publication of the International Association for the Study of Lung Cancer 4:1280-1288
4. Hirsh V, Tchekmedyian NS, Rosen LS, Zheng M, Hei YJ (2004) Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer 6:170-174
5. Coleman RE (2004) Bisphosphonates: clinical experience. Oncologist 9(Suppl 4):14-27
6. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100:2613-2621
7. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study group. J Clin Oncol 21:3150-3157
8. Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD (2006) Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev 4:CD006250
9. Piga A, Bracci R, Ferretti B, Sandri P, Nortilli R, Acito L, Pancotti A, Di Furia L, Carle F, Cellerino R (1998) A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy. J Exp Clin Cancer Res 17:213-217
10. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI (2002) Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168:1005-1007
11. Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT (2010) Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 184:162-167
12. Bloomfield DJ (1998) Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol 16:1218-1225
13. Bonjour JP, Rizzoli R (1991) Treatment of hypercalcaemia of malignancy with clodronate. Bone 12(Suppl 1):S19-S23
14. Hitron A, Adams V (2009) The pharmacological management of skeletal-related events from metastatic tumors. Orthopedics 32:188
15. Price N (2004) Bisphosphonates to prevent skeletal morbidity in patients with lung cancer with bone metastases. Clin Lung Cancer 5:267-269
16. Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M, Glasmacher A (2002) Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 3:CD003188
17. Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev 3:CD003474
18. Calderone R, Nimako K, Leary A, Popat S, O'Brien ME (2011) Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease - a short communication. Eur J Cancer 47:1603-1605
19. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis J, Clarke M, Devereaux P, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1-e34
20. Furlan AD, Pennick V, Bombardier C, van Tulder M (2009) 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine (Phila Pa 1976) 34:1929-1941
21. van der Velde G, van Tulder M, Cote P, Hogg-Johnson S, Aker P, Cassidy JD, Carragee E, Carroll L, Guzman J, Haldeman S, Holm L, Hurwitz E, Nordin M, Peloso P (2007) The sensitivity of review results to methods used to appraise and incorporate trial quality into data synthesis. Spine (Phila Pa 1976) 32:796-806
22. Bradburn MJ, Deeks JJ, Altman DG (1998) Metan - a command for meta-analysis in STATA. STB 44:4-15
23. Harris RJ, Bradburn MJ, Deeks JJ, Harbord RM, Altman DG, Jac S (2008) Metan: fixed- and random-effects metaanalysis. Stata J 8:3-28
24. Borenstein M, Hedges L, Higgins J, H. R (2005) Comprehensive meta-analysis version 2. In: Editor (ed) Book comprehensive metaanalysis version 2. Biostat, City
25. Francini F, Pascucci A, Bargagli G, Francini E, Conca R, Miano ST, Martellucci I, Migali C, Gotti G, Fiaschi AI, Cozzolino A, Petrioli R (2011) Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer. Int J Clin Oncol 16:264-269
26. Guo C, Guo Q, Qi J, Liu Q, Wu N (2008) Comparison of the effects of Ibandronate and Bonefos on non-small cell lung cancer with bone metastases. Chin J Clin Oncol 35:310-312
27. HirshV,Major PP, LiptonA, CookRJ, Langer CJ, SmithMR, Brown JE, Coleman RE (2008) Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol: Official Publication of the International Association for the Study of Lung Cancer 3:228-236
28. Li XX, Zhou TC, Zhao J (2003) Clinical evaluation of combinedmodality therapy for bone metastasis of non-small-cell lung cancer. Di Yi Jun Yi Da Xue Xue Bao 23:752-753
29. Zhang S, Liu G, Hu F (1999) A clinical trial of Bonin in the bone metastases of lung cancer. Chin J Clin Oncol 26:445-447
30. Su J, You C, Cai S, Meng Y (2002) 89SrCl2 and/or bonefos in the treatment of bone metastasis from pulmonary carcinoma. Chin J Lung Cancer 5:357-359
31. Zarogoulidis K, Boutsikou E, Zarogoulidis P, Eleftheriadou E, Kontakiotis T, Lithoxopoulou H, Tzanakakis G, Kanakis I, Karamanos NK (2009) The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 125:1705-1709
32. Zheng T, Chen W (2004) Evaluation on the effect of acesodyne treatment in patient with lung cancer bone metastasis. Chin J Clin Rehabil 8:5714-5715
33. Pandya KJ, Gajra A, Warsi GM, Argonza-Aviles E, Ericson SG, Wozniak AJ (2010) Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer. Lung Cancer 67:330-338
34. Kritikos K, Heras P, Hatzopoulos A, Androutsos N (2008) Efficacy and safety of intravenous zoledronic acid 4 mg infused over 15 minutes: results from a 2-year study of lung cancer patients with metastatic bone disease. Ann Oncol 19:viii286-viii287
35. Zarogoulidis K, Boutsikou E, Zarogoulidou V, Lithoxopoulou H, Tsiouda T, Ballasoulis G, Kontakiotis T (2009) The impact of bisphosphonate therapy on survival of lung cancer patients with bone metastasis. Pneumon 22:25-37
36. Hirai F, Murakami H, Yamamoto N, Yamanaka T, Okamoto I, Sawa T, Hirashima T, Takeda K, Fukuoka M, Nakagawa K (2011) Randomized phase II trial of zoledronic acid in combination with docetaxel in previously treated non-small cell lung cancer (NSCLC) patients with bone metastases - result of a west Japan oncology group study. Eur J Cancer, Supplement 47: S628
37. Scagliotti G, C. M, De Marinis F, Engel-Riedel W, Albert I, Sallo V, Chen YM, Perez JR, Kosmidis P (2011) A study to evaluate the safety and efficacy of zoledronic acid in the prevention or delaying of bone metastasis in patients with stage IIIA and IIIB non-small cell lung cancer. Clinical Trialsgov NCT00172042: Available< >(accessed on December 00172012, 00172011)
38. Scagliotti G, Manegold C, Kosmidis P, Kirner A (2006) Efficacy of zoledronic acid for the prevention of bone metastases in patients with non-small cell lung cancer. Bone 38:S83-S83
39. Scagliotti G, Manegold C, De Marinis F, Engel-Riedel W, Albert I, Sallo V, Chen YM, Perez JR, Kosmidis P (2009) Evaluating the efficacy of zoledronic acid for the prevention of disease progression in patients with non-small cell lung cancer (NSCLC). Eur J Cancer, Supplement 7: 522
40. Manas A, Casas F, Ciria JP, Lopez C, Saez J, Palacios A, de las Heras M, Porto C, Sanchez E, Martin C, Esco R, Veiras C, Martinez JC, Marquez M, Ramos A, Calvo F, Fuertes J, Andreu FJ, Contreras J, Perez L, Romero J, Vayreda J, Victoria C (2008) Randomised study of single dose (8 Gy vs. 6 Gy) of analgesic radiotherapy plus zoledronic acid in patients with bone metastases. Clin Transl Oncol 10:281-287
41. Roqué i Figuls M, Martinez-Zapata M, JoséAlonso-Coello P, Català E, Garcia Jose L, Ferrandiz M (2003) Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev 6:CD003347
42. Sze WM, Shelley M, Held I, Mason M (2004) Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy. Cochrane Database Syst Rev 2:CD004721
43. Wong R, Wiffen PJ (2002) Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev 2: CD002068
44. Rosen L, Gordon D, Tchekmedyian S, Hirsh V, Yanagihara R, Coleman R (2004) Long-term zoledronic acid therapy is effective and safe for reducing the risk of skeletal complications in patients with non-small cell lung cancer (NSCLC) and bone metastases. Bone 34:S89
45. Rosen LS (2002) Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors. Semin Oncol 29:28-32
46. Brown J, Cook R, Hirsh V, Major P (2008) Risk factors for skeletal-related event in zoledronic acid-treated patients with bone metastases from non-small cell lung cancer. Ann Oncol 19:viii275
47. Athanassiou E, Kyrgias G, Panoussaki E, Christodoulidou M, Pantelakos P, Skarlos DV, Karpasitis N (1994) Response of patients with bone metastasis of breast, lung and prostate cancer to radiation therapy (RT) alone, versus radiation therapy and diphosphonate (pamidronate). Ann Oncol Suppl 8:200
48. Coleman R, Cook R, Saad F, Hirsh V, Major P, Dias R, Lipton A (2008) Effects of zoledronic acid on survival in patients with metastatic bone disease and high bone turnover: results from a meta-analysis. Ann Oncol 19:viii276
49. Altieri AM, Portalone L, Alimonti A, Antilli A, Barbera S, Nunziati F, Perrone N, Signora M (2000) Pamidronate versus radiotherapy in the treatment of bone metastases by lung cancer: a randomized AIPO Chest Oncology Study Group trial. Ann Oncol 11:672P
50. Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, Keane M, Gil M, Davies C, Burkinshaw R, Houston SJ, Grieve RJ, Barrett-Lee PJ, Thorpe H (2011) Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. Breast Cancer Res Treat 127:429-438
51. Kotteas E, Alamara C, Kiagia M, Pantazopoulos K, Boufas A, Provata A, Charpidou A, Syrigos KN (2008) Safety and efficacy of zoledronic acid rapid infusion in lung cancer patients with bone metastases: a single institution experience. Anticancer Res 28:529-533
52. Kretzschmar A, Wiegel T, Al-Batran SE, Hinrichs HF, Kindler M, Steck T, Illiger HJ, Heinemann V, Schmidt K, Haus U, Kirner A, Ehninger G (2007) Rapid and sustained influence of intravenous zoledronic acid on course of pain and analgesics consumption in patients with cancer with bone metastases: a multicenter open-label study over 1 year. Support Cancer Ther 4:203-210
53. Shi X, Teng LS, Yu XM, Ma SL (2008) Clinical comparative study of zoledronic acid versus pamidronate disodium in the treatment of pain of skeletal metastases lung cancer. Chin J Cancer Prev Treat 15:707-708
54. Pandey R, Dey S, Mukhopadhyay A (2009) The better bisphosphonate in patients with bone metastasis: zoledronic acid or ibandronic acid? A study from Eastern India. J Clin Oncol 27:e20524
55. Coleman R, Burkinshaw R, Winter M, Neville-Webbe H, Lester J, Woodward E, Brown J (2010) Zoledronic acid. Expert Opinion Drug Safety 10:133-145
56. Coleman R, Cook R, Hirsh V, Major P, Lipton A (2011) Zoledronic acid use in cancer patients: more than just supportive care? Cancer 117:11-23
57. Coleman RE, Seaman JJ (2001) The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases. Semin Oncol 28:11-16
58. Botteman MF, Logman JFS, Kaura S (2009) Cost-effectiveness assessment of zoledronic acid (ZOL) relative to placebo (PBO) in the treatment of lung cancer patients with skeletal metastases in five European countries. Value Health 12:A271
59. Joshi AD, Carter JA, Botteman MF, Kaura S (2011) Costeffectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, The Netherlands, and the United Kingdom. Clin Ther 33:291-304
60. Carter JA, Joshi AD, Kaura S, Botteman MF (2012) Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours. PharmacoEconomics 30:373-386
61. Berenson J, Hirschberg R (2004) Safety and convenience of a 15- minute infusion of zoledronic acid. Oncologist 9:319-329
62. Di Salvatore M, Orlandi A, Bagala C, Quirino M, Cassano A, Astone A, Barone C (2011) Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line. Cell Proliferation 44:139-146
63. Gnant M, Clezardin P (2011) Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treatment Reviews (epub ahead of print)
64. Hirsh V (2011) Bisphosphonates in lung cancer: can they provide benefits beyond prevention of skeletal morbidity? Anti-cancer Agents Medicinal Chemistry (epub ahead of print)